Beneficial effects of combined benazepril-amiodipine on cardiac nitric oxide, cGMP, and TNF-α production after cardiac ischemia

被引:41
作者
Siragy, Helmy M.
Xue, Chun
Webb, Randy L.
机构
[1] Univ Virginia, Hlth Syst, Dept Med, Charlottesville, VA USA
[2] Novartis Inst Biomed Res, E Hanover, NJ USA
关键词
amlodipine; angiotensin II; benazepril; cardiac interstitial fluid; cardiac ischemia; cGMP; nitric oxide; TNF-alpha;
D O I
10.1097/01.fjc.0000211750.01326.b3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this study was to determine if myocardial inflammation is increased after myocardial ischemia and whether angiotensin-converting enzyme inhibitors, calcium channel blockers, or diuretics decrease mediators of inflammation in rats with induced myocardial ischemia. Changes in cardiac interstitial fluid (CIF) levels of nitric oxide metabolites (NOX), cyclic guanosine 3',5'-monophosphate (cGMP), angiotensin II (Ang II), and tumor necrosis factor-alpha (TNF-alpha) were monitored with/without oral administration of benazepril, amlodipine, combined benazepril-amlodipine, or hydrochlorothiazide. Using a microdialysis technique, levels of several mediators of inflammation were measured after sham operation or 30-minute occlusion of the left anterior descending coronary artery. Compared with sham animals, levels of CIF NOX and cGMP were decreased in animals with ischemia (P < 0.00 1). Benazepril or amlodipine significantly increased NOX levels (P < 0.05 vs. untreated ischemia), but only benazepril significantly increased cGMP (P < 0.05). Combined benazepril-amlodipine further increased CIF NOX and cGMP (P < 0.001), compared with either drug alone. CIF Ang II and TNF-alpha in sham animals did not change significantly. In animals with ischemia, CIF Ang II and TNF-alpha increased progressively. Amlodipine alone, benazepril alone, or combined benazepril-amlodipine significantly reduced TNF-alpha (P < 0.01 for monotherapies and P < 0.001 for combination therapy). Hydrochlorothiazide did not cause significant changes in NOX, cGMP, or TNF-alpha. Combination benazepril-amlodipine may be beneficial for managing cardiac ischemia.
引用
收藏
页码:636 / 642
页数:7
相关论文
共 37 条
[1]  
*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981
[2]   Nifedipine limits infarct size via NO-dependent mechanisms in dogs [J].
Asanuma, H ;
Kitakaze, M ;
Funaya, H ;
Takashima, S ;
Minamino, T ;
Node, K ;
Sakata, Y ;
Asakura, M ;
Sanada, S ;
Shinozaki, Y ;
Mori, H ;
Kuzuya, T ;
Tada, M ;
Hori, M .
BASIC RESEARCH IN CARDIOLOGY, 2001, 96 (05) :497-505
[3]  
BALL SG, 1993, LANCET, V342, P821
[4]   Putting the brakes on cardiac hypertrophy - Exploiting the NO-cGMP counter-regulatory system [J].
Booz, GW .
HYPERTENSION, 2005, 45 (03) :341-346
[5]   Amlodipine inhibits pro-inflammatory cytokines and free radical production and inducible nitric oxide synthase expression in lipopolysaccharide/interferon-γ-stimulated cultured vascular smooth muscle cells [J].
Chou, TC ;
Yang, SP ;
Pei, D .
JAPANESE JOURNAL OF PHARMACOLOGY, 2002, 89 (02) :157-163
[6]   Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial [J].
Dahlöf, B ;
Sever, PS ;
Poulter, NR ;
Wedel, H ;
Beevers, DG ;
Caulfield, M ;
Collins, R ;
Kjeldsen, SE ;
Kristinsson, A ;
McInnes, GT ;
Mehlsen, J ;
Nieminen, M ;
O'Brien, E ;
Östergren, J .
LANCET, 2005, 366 (9489) :895-906
[7]   Tissue angiotensin and pathobiology of vascular disease - A unifying hypothesis [J].
Dzau, VJ .
HYPERTENSION, 2001, 37 (04) :1047-1052
[8]  
Faulkner M A, 2001, Expert Opin Pharmacother, V2, P165, DOI 10.1517/14656566.2.1.165
[9]   Angiotensin converting enzyme inhibitor calcium antagonist combination: An alliance for cardioprotection? [J].
Ferrari, R .
JOURNAL OF HYPERTENSION, 1997, 15 :S109-S117
[10]   NO modulates myocardial O2 consumption in the nonhuman primate:: an additional mechanism of action of amlodipine [J].
Forfia, PR ;
Zhang, XP ;
Knight, DR ;
Smith, AH ;
Doe, CPA ;
Wolfgang, EA ;
Flynn, DM ;
Wolin, MS ;
Hintze, TH .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1999, 276 (06) :H2069-H2075